10 PhD positions within tumor treatment

The European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry (EN-ACTI2NG), formed by 12 academic, clinical and industrial institutions from Spain, Austria, Germany, The Netherlands and the United Kingdom offers a multidisciplinary training for 10 early stage researchers in the development and analysis of engineered tumor-specific immune receptors. This network, funded by the H2020 Marie Sklodowska Curie Action program, emanates from recent clinical evidence that T cells expressing engineered tumor-specific immune receptors can eradicate tumors that do not respond to conventional treatment. This important therapeutic approach is in a very early phase of development and requires a well-trained workforce to address challenges such as development of tumor-specific receptors for a wider array of tumors, improvement in efficiency of these receptors, better on/off-target toxicity safety profiles and more efficient transfer of basic research findings to the clinic.

Application not later than May 1st 2017

Find out more

PhD Thesis program in Vienna

Dear Members of the SSI,

we are writing you to you to inform you that we are currently recruiting highly
talented PhD students for an International PhD Thesis program at the Medical University of Vienna in the field of Molecular, Cellular and Clinical Allergology, MCCA (see attachment and web-site at: http://www.phd-mcca.at/).

We kindly ask you to distribute the announcement (see attachment) to your best students. The program is very attractive because it offers three years (with an option for a fourth year) of full salary and a budget for materials to the students. Students can select among several projects and group leaders. They must have an Masters degree, or MD or equivalent (obtain the degree at latest by September 30, 2017) and must be prepared to take part in a competitive selection process.

Over the last years we have successfully recruited and enrolled 30 international students into the program, this is now the third call for highly interested and talented students (start of employment October 1, 2017).

We trust, that you will know the one or other highly talented student and we
kindly ask you to distribute the announcement to those candidates. The deadline for the applications has been extended to May 2, 2017.

We thank you very much for helping us recruiting the best students of the world into our
program. It will be our pride to teach and educate them in the best possible way.

With best personal regards from Vienna,

Winfried PICKL and Rudolf VALENTA

MCCA Speaker and MCCA Deputy Speaker

Postdoctoral position in Mucosal Immunology

A postdoctoral position is available in the Mucosal Immunology group headed by Professor William Agace at the Division of Immunology and Vaccinology, at the Danish Technical University, Veterinary Institute, Frederiksberg/Lyngby.

Application deadline: 31/1-2017.

Find out more


At the Faculty of Medicine, Department of Health Science and Technology a 3 year position as PhD student within Immunology is a PhD stipend is available within the general study programme “Clinical Science and Biomedicine” from 1 February, 2017 or soon thereafter.

Deadline: Monday Dec 19th 2016.

Find out more

Postdoctoral fellow in Immunology / Rheumatology


At the Department of rheumatology and inflammation research, translational studies on inflammation caused by e.g. autoimmunity, allergy and infection are conducted with the aim to determine mechanisms involved in tissue inflammation. Projects at the department range from basic research and animal models, to clinical trials and rehabilitation of patients.

Our research group studies the influence of sex hormones on the immune system during inflammatory diseases and inflammation-induced osteoporosis.

Find out more

Early Stage Researcher (PhD Students) Münich

Project Leaders: Prof. Stefan Endres, Coordinator of IMMUTRAIN, Director of the Division of Clinical Pharmacology, Ludwig-Maximilians-Universitaet, Munich
PD Dr. Sebastian Kobold, Scientific Coordinator of IMMUTRAIN, Group Leader of Immunopharmacology, Division of Clinical Pharmacology, Ludwig Maximilians Universitaet, Munich

Description of the project: Adoptive T cell transfer for cancer therapy The project will be part of the IMMUTRAIN-Workpackage 1: Combination of antibodies with adoptive T cell transfer. It will comprise: Genetic engineering of T-cells for
enhanced functionality against cancer- Validation in different animal models – Function analysis and description of cellular product.

Application deadline September 9th 2016

Find out more